Global InformationPeter Grootenhuis information
 | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (May 2024) |
Peter Grootenhuis (March 1960 – August 2019) was a Dutch-American Medicinal Chemist. Grootenhuis was the Project Leader and Co-Inventor of Ivacaftor (VX-770), the first CFTR potentiator FDA approved drug to treat the underlying cause of Cystic Fibrosis (CF) in patients with certain mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene (primarily the G551D mutation.[1]), who account for 4-5% of CF cases. Grootenhuis also led the Vertex team to subsequent discovery of Orkambi, the combination of Ivacaftor and Lumacaftor(VX-809), approved to treat CF in people with two copies of the F508del mutation (~ 50% of CF patients).[2] Most recently, Grootenhuis's team discovered Tezacaftor (VX-661) and Elexacaftor (VX-445),[3] which in combination with Ivacaftor are the components of Trikafta, a drug approved by the FDA in 2019 to treat CF in more than 90% of CF patients.[4] For Grootenhuis’ contributions to the discovery of these compounds, he was awarded the 2018 IUPAC Richter Prize,[5] the American Chemical Society’s 2013 Heroes of Chemistry Award,[6] and inducted into the American Chemical Society Division of Medicinal Chemistry Hall of Fame.[7] Grootenhuis has contributed to the discovery of over 11 clinical candidates, co-authored more than 100 peer reviewed papers and is inventor of 65 + U.S Patents, and more than 50 EU Patents.[8]
- ^ Sermet-Gaudelus, Isabelle (2013-03-01). "Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation". European Respiratory Review. 22 (127): 66–71. doi:10.1183/09059180.00008512. ISSN 0905-9180. PMC 9487423. PMID 23457167. S2CID 16564925.
- ^ "Our Scientists Power Science | Vertex Pharmaceuticals". www.vrtx.com. Retrieved 2020-09-30.
- ^ "Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations". MDLinx. Retrieved 2020-07-21.
- ^ Commissioner, Office of the (2020-03-24). "FDA approves new breakthrough therapy for cystic fibrosis". FDA. Retrieved 2020-07-21.
- ^ "Peter D.J. Grootenhuis is awarded the 2018 IUPAC-Richter Prize". IUPAC | International Union of Pure and Applied Chemistry. 2018-01-23. Retrieved 2020-07-21.
- ^ "New 'Heroes of Chemistry' developed products that improve health and protect food supply". American Chemical Society. Retrieved 2020-07-21.
- ^ "MEDI Hall of Fame Inductees". www.acsmedchem.org. Retrieved 2020-07-21.
- ^ "Peter Grootenhuis, Ph.D." www.acsmedchem.org. Retrieved 2020-07-21.